Journal of Surgery Concepts & Practice >

2023 , Vol. 28 >Issue 06: 512 - 519

DOI: https://doi.org/10.16139/j.1007-9610.2023.06.05

Experts forum

Interpretation of the 2022 edition of “guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis in China”

Expand
  • Department of Endocrinology, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200336, China

Received date: 2023-11-20

  Online published: 2024-03-04

Fold

Abstract

“Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis in China” (2022) (referred to as the “guidelines”) was officially published in August 2022 in the Chinese Journal of Endocrine Metabolism. These guidelines have been extensively updated from the 2007 version, with 15 sections covering the etiology, clinical manifestations, diagnosis, evaluation, and treatment of hyperthyroidism, as well as the management of specific types of thyrotoxicosis. The new version guidelines proposed 107 recommended opinions supported by stronger evidence, offering comprehensive and reliable guidance for clinical doctors and medical professionals dealing with thyrotoxicosis. This article aimed to extract the key points and recommended strategies from the guidelines to help clinical doctors better understand and apply the latest guiding principles.

Key words： Thyrotoxicosis; Hyperthyroidism; Thyroid crisis; Graves ophthalmopathy; Guide Interpretation

Cite this article

XU Bojin, PENG Wenfang, HUANG Shan . Interpretation of the 2022 edition of “guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis in China”[J]. Journal of Surgery Concepts & Practice, 2023 , 28(06) : 512 -519 . DOI: 10.16139/j.1007-9610.2023.06.05

References

[1] 中华医学会内分泌学分会, 中国医师协会内分泌代谢科医师分会, 中华医学会核医学分会, 等. 中国甲状腺功能亢进症和其他原因所致甲状腺毒症诊治指南[J]. 中华内分泌代谢杂志, 2022, 38(8):700-748.
  Chinese Society of Endocrinology, Chinese Endocrinologist Association, Chinese Society of Nuclear Medicine, et al. Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Chin J Endocrinol Metab, 2022, 38(8):700-748.
[2] AKAMIZU T, SATOH T, ISOZAKI O, et al. Diagnostic criteria, clinical features, and incidence of thyroid storm based on nationwide surveys[J]. Thyroid, 2012, 22(7):661-679.
[3] ANGELL T E, LECHNER M G, NGUYEN C T, et al. Clinical features and hospital outcomes in thyroid storm: a retrospective cohort study[J]. J Clin Endocrinol Metab, 2015, 100(2):451-459.
[4] LIU X, QIANG W, LIU X, et al. A second course of antithyroid drug therapy for recurrent Graves’ disease: an experience in endocrine practice[J]. Eur J Endocrinol, 2015, 172(3):321-326.
[5] ROSS D S, BURCH H B, COOPER D S, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10):1343-1421.
[6] BURCH H B, COOPER D S. Management of Graves di-sease: a review[J]. JAMA, 2015, 314(23):2544-2554.
[7] ROSS D S. Radioiodine therapy for hyperthyroidism[J]. N Engl J Med, 2011, 364(6):542-550.
[8] KANDIL E, MOHAMED S E, DENIWAR A, et al. Electrophysiologic identification and monitoring of the external branch of superior laryngeal nerve during thyroidectomy[J]. Laryngoscope, 2015, 125(8):1996-2000.
[9] GENCER B, COLLET T H, VIRGINI V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts[J]. Circulation, 2012, 126(9):1040-1049.
[10] BLUM M R, BAUER D C, COLLET T H, et al. Subclinical thyroid dysfunction and fracture risk: a meta-analysis[J]. JAMA, 2015, 313(20):2055-2065.
[11] KALMIJN S, MEHTA K M, POLS H A, et al. Subclinical hyperthyroidism and the risk of dementia. The Rotterdam study[J]. Clin Endocrinol(Oxf), 2000, 53(6):733-737.
[12] BARTLEY G B, GORMAN C A. Diagnostic criteria for Graves' ophthalmopathy[J]. Am J Ophthalmol, 1995, 119(6):792-795.
[13] BARTALENA L, KAHALY G J, BALDESCHI L, et al. The 2021 European Group on Graves' Orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy[J]. Eur J Endocrinol, 2021, 185(4):G43-G67.
[14] KAHALY G J. Imaging in thyroid-associated orbitopathy[J]. Eur J Endocrinol, 2001, 145(2):107-118.
[15] ANDERSEN S L, KN?SGAARD L. Management of thyrotoxicosis during pregnancy[J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(4):101414.
[16] DUNTAS L H. Thyroid function in aging: a discerning approach[J]. Rejuvenation Res, 2018, 21(1):22-28.
Options
Outlines

/

〈 〉